

In a prospective, representative sample of patients with Xpert-tested rifampicin-resistant tuberculosis, we found an elevated prevalence of bedaquiline resistance, particularly in patients with recent tuberculosis treatment. Efficient and accurate surveillance for bedaquiline resistance should be a high programmatic priority.
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet
Microbe / Infectious Research
|11th Mar, 2026
|The Lancet